Corticosteroids, but not TNF Antagonists, Associate With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases

Increasing age, comorbidities, and use of corticosteroids and other anti-inflammatory agents correlated with severe COVID-19 in patients with inflammatory bowel diseases (IBD), whereas treatment with tumor necrosis factor (TNF) antagonists did not, researchers report in Gastroenterology. Corticosteroids, immunomodulators (thiopurines, methotrexate), and biologic agents (TNF antagonists such as infliximab) are commonly

Read more
  • AGA Clinical Practice Update: Pause IBD Meds For Patients With COVID-19

AGA Clinical Practice Update: Pause IBD Meds For Patients With COVID-19

Patients with inflammatory bowel diseases (IBD) with COVID-19 should delay biological therapies, restarting them once symptoms are gone, says a clinical practice update from the American Gastroenterological Association (AGA). The practice update, written by David T Rubin et al, says that patients with IBD who test positive for SARS-CoV-2 but

Read more

REVIEW: Transitioning Adolescents With Inflammatory Bowel Diseases to Adult Care

Adolescents and young adults diagnosed with inflammatory bowel diseases (IBDs) in pediatric care are vulnerable during their transition to adult care. A review article in the February issue of Clinical Gastroenterology and Hepatology discusses the transition from pediatric to adult care for IBD, makes recommendations to improve this process, and identifies

Read more
  • AGA Clinical Practice Guideline: Management of Moderate to Severe Ulcerative Colitis

AGA Clinical Practice Guideline: Management of Moderate to Severe Ulcerative Colitis

The AGA’s latest guideline provides recommendations for the management of adult outpatients with moderate to severe ulcerative colitis (UC) and adult hospitalized patients with acute severe UC. The guideline, written by Joseph D. Feuerstein et al, discusses the use of immunomodulators, biologics, and small molecules to induce and maintain remission

Read more
  • IBD Research Highlights from 2019 ECCO Congress

IBD Research Highlights from 2019 ECCO Congress

A variety of exciting findings from inflammatory bowel disease (IBD) research were presented at the Congress of the European Crohn’s and Colitis Organisation (ECCO), held in Copenhagen, March 7–9. Shixian Hu (Universitair Medisch Centrum Groningen, The Netherlands) reported on associations between genetic factors and the microbiome in patients with IBD.

Read more
  • Is it Safe or Effective to Combine Therapies for Inflammatory Bowel Diseases?

Is it Safe or Effective to Combine Therapies for Inflammatory Bowel Diseases?

Little is known about the efficacy and safety of combination targeted therapy for inflammatory bowel diseases (IBD), despite their use in treatment of other immune-mediated disorders. In a review article in the September issue of Clinical Gastroenterology and Hepatology, Robert P. Hirten et al discuss findings from studies of biologic

Read more
  • Are Patients With PSC and Colitis More likely to Have Subclinical Inflammation?

Are Patients With PSC and Colitis More likely to Have Subclinical Inflammation?

Patients with primary sclerosing cholangitis (PSC) and ulcerative colitis (UC) in remission are significantly more likely to have inflammation of the right colon, based on endoscopic and histologic markers, than patients with UC without PSC, researchers report in the January issue of Clinical Gastroenterology and Hepatology. These findings provide insight into cause

Read more
  • Does Immunomodulator Therapy for IBD During Pregnancy Affect Newborn Response to Vaccines?

Does Immunomodulator Therapy for IBD During Pregnancy Affect Newborn Response to Vaccines?

Rates of adequate serologic response to Haemophilus influenzae B (HiB) and tetanus vaccines are similar among infants born to women with inflammatory bowel diseases (IBD) treated with immunomodulator or biologic agents compared to women who did not receive these immunosuppressive drugs during pregnancy, researchers report in the January issue of Clinical Gastroenterology

Read more
  • 3-D Imaging of T-cell Localization in Inflamed Colon Tissues

3-D Imaging of T-cell Localization in Inflamed Colon Tissues

Light sheet fluorescence microscopy (LSFM) provides accurate 3-dimensional images of inflammed intestine of mice with colitis, researchers show in a Gastroenterology in Motion article and video in the October issue of Gastroenterology. The authors demonstrate use of the technology to analyze migration of human T cells in colons of mice with colitis. Improved techniques are

Read more
  • Does Consumption of Certain Fatty Acids Increase Risk of Ulcerative Colitis Flares?

Does Consumption of Certain Fatty Acids Increase Risk of Ulcerative Colitis Flares?

Diets with high levels of fatty acids such as myristic acid (found in palm oil, coconut oil, and dairy fats) increased risk of flare in patients with ulcerative colitis (UC), researchers report in the September issue of Clinical Gastroenterology and Hepatology. Their findings, from a prospective study of more than 400 patients

Read more